Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.73
BIO.B's Cash to Debt is ranked lower than
56% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.19 vs. BIO.B: 1.73 )
Ranked among companies with meaningful Cash to Debt only.
BIO.B' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.81 Max: 1.81
Current: 1.73
0.04
1.81
Equity to Asset 0.68
BIO.B's Equity to Asset is ranked higher than
62% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. BIO.B: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
BIO.B' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.53 Max: 0.68
Current: 0.68
0.33
0.68
Interest Coverage 7.10
BIO.B's Interest Coverage is ranked lower than
72% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.72 vs. BIO.B: 7.10 )
Ranked among companies with meaningful Interest Coverage only.
BIO.B' s Interest Coverage Range Over the Past 10 Years
Min: 2.77  Med: 4.97 Max: 7.69
Current: 7.1
2.77
7.69
F-Score: 7
Z-Score: 3.85
M-Score: -2.32
WACC vs ROIC
7.60%
5.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.83
BIO.B's Operating margin (%) is ranked higher than
63% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.61 vs. BIO.B: 7.83 )
Ranked among companies with meaningful Operating margin (%) only.
BIO.B' s Operating margin (%) Range Over the Past 10 Years
Min: 6.9  Med: 10.92 Max: 14.74
Current: 7.83
6.9
14.74
Net-margin (%) 5.33
BIO.B's Net-margin (%) is ranked higher than
62% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.03 vs. BIO.B: 5.33 )
Ranked among companies with meaningful Net-margin (%) only.
BIO.B' s Net-margin (%) Range Over the Past 10 Years
Min: 3.65  Med: 7.14 Max: 9.63
Current: 5.33
3.65
9.63
ROE (%) 4.47
BIO.B's ROE (%) is ranked higher than
57% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.56 vs. BIO.B: 4.47 )
Ranked among companies with meaningful ROE (%) only.
BIO.B' s ROE (%) Range Over the Past 10 Years
Min: 3.7  Med: 9.64 Max: 13.98
Current: 4.47
3.7
13.98
ROA (%) 2.99
BIO.B's ROA (%) is ranked higher than
63% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.35 vs. BIO.B: 2.99 )
Ranked among companies with meaningful ROA (%) only.
BIO.B' s ROA (%) Range Over the Past 10 Years
Min: 2.28  Med: 5.11 Max: 6.83
Current: 2.99
2.28
6.83
ROC (Joel Greenblatt) (%) 15.80
BIO.B's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.16 vs. BIO.B: 15.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIO.B' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 14.79  Med: 27.69 Max: 36.51
Current: 15.8
14.79
36.51
Revenue Growth (3Y)(%) -1.70
BIO.B's Revenue Growth (3Y)(%) is ranked lower than
62% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. BIO.B: -1.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIO.B' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.7  Med: 8.90 Max: 21.6
Current: -1.7
-1.7
21.6
EBITDA Growth (3Y)(%) -10.30
BIO.B's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. BIO.B: -10.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIO.B' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.3  Med: 8.60 Max: 41.3
Current: -10.3
-10.3
41.3
EPS Growth (3Y)(%) -12.40
BIO.B's EPS Growth (3Y)(%) is ranked lower than
66% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. BIO.B: -12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIO.B' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.8  Med: 10.70 Max: 75.7
Current: -12.4
-25.8
75.7
» BIO.B's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BIO.B

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:VWR, NAS:BRKR, NYSE:CRL, NYSE:ALR, NAS:ICLR, NAS:QGEN, NYSE:WX, OTCPK:DSRLF, OTCPK:SWTUY, OTCPK:BMXMF, NAS:PRXL, OTCPK:CZMWY, OTCPK:ERFSF, NYSE:PKI, NAS:PRAH, NAS:DXCM, NAS:CPHD, NAS:MYGN, NAS:INCR, NAS:NEOG » details
Traded in other countries:BUWA.Germany,
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a wide customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissio

Ratios

vs
industry
vs
history
P/E(ttm) 38.50
BIO.B's P/E(ttm) is ranked lower than
63% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.35 vs. BIO.B: 38.50 )
Ranked among companies with meaningful P/E(ttm) only.
BIO.B' s P/E(ttm) Range Over the Past 10 Years
Min: 13.68  Med: 21.55 Max: 58.63
Current: 38.5
13.68
58.63
PE(NRI) 38.50
BIO.B's PE(NRI) is ranked lower than
64% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.37 vs. BIO.B: 38.50 )
Ranked among companies with meaningful PE(NRI) only.
BIO.B' s PE(NRI) Range Over the Past 10 Years
Min: 13.68  Med: 21.87 Max: 58.61
Current: 38.5
13.68
58.61
Price/Owner Earnings (ttm) 108.57
BIO.B's Price/Owner Earnings (ttm) is ranked lower than
90% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.79 vs. BIO.B: 108.57 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BIO.B' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.69  Med: 19.85 Max: 134.78
Current: 108.57
9.69
134.78
P/B 1.63
BIO.B's P/B is ranked higher than
81% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.19 vs. BIO.B: 1.63 )
Ranked among companies with meaningful P/B only.
BIO.B' s P/B Range Over the Past 10 Years
Min: 1.45  Med: 1.84 Max: 3.02
Current: 1.63
1.45
3.02
P/S 2.06
BIO.B's P/S is ranked higher than
66% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.09 vs. BIO.B: 2.06 )
Ranked among companies with meaningful P/S only.
BIO.B' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 1.54 Max: 2.17
Current: 2.06
0.87
2.17
PFCF 106.03
BIO.B's PFCF is ranked lower than
92% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.89 vs. BIO.B: 106.03 )
Ranked among companies with meaningful PFCF only.
BIO.B' s PFCF Range Over the Past 10 Years
Min: 9.61  Med: 24.52 Max: 469.08
Current: 106.03
9.61
469.08
POCF 27.76
BIO.B's POCF is ranked lower than
72% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.78 vs. BIO.B: 27.76 )
Ranked among companies with meaningful POCF only.
BIO.B' s POCF Range Over the Past 10 Years
Min: 7.48  Med: 13.03 Max: 45.73
Current: 27.76
7.48
45.73
EV-to-EBIT 23.66
BIO.B's EV-to-EBIT is ranked lower than
62% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.91 vs. BIO.B: 23.66 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO.B' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 13.00 Max: 26.5
Current: 23.66
8.4
26.5
EV-to-EBITDA 12.95
BIO.B's EV-to-EBITDA is ranked higher than
54% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.08 vs. BIO.B: 12.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIO.B' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 8.90 Max: 15.9
Current: 12.95
6
15.9
Shiller P/E 30.23
BIO.B's Shiller P/E is ranked higher than
67% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.36 vs. BIO.B: 30.23 )
Ranked among companies with meaningful Shiller P/E only.
BIO.B' s Shiller P/E Range Over the Past 10 Years
Min: 19.56  Med: 27.88 Max: 42.78
Current: 30.23
19.56
42.78
Current Ratio 4.43
BIO.B's Current Ratio is ranked higher than
71% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.85 vs. BIO.B: 4.43 )
Ranked among companies with meaningful Current Ratio only.
BIO.B' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 2.98 Max: 4.52
Current: 4.43
1.87
4.52
Quick Ratio 3.10
BIO.B's Quick Ratio is ranked higher than
60% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BIO.B: 3.10 )
Ranked among companies with meaningful Quick Ratio only.
BIO.B' s Quick Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.23 Max: 3.45
Current: 3.1
1.22
3.45
Days Inventory 203.54
BIO.B's Days Inventory is ranked lower than
87% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. BIO.B: 203.54 )
Ranked among companies with meaningful Days Inventory only.
BIO.B' s Days Inventory Range Over the Past 10 Years
Min: 151.29  Med: 169.28 Max: 195.4
Current: 203.54
151.29
195.4
Days Sales Outstanding 68.94
BIO.B's Days Sales Outstanding is ranked lower than
58% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. BIO.B: 68.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO.B' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.37  Med: 70.75 Max: 89.45
Current: 68.94
63.37
89.45
Days Payable 49.51
BIO.B's Days Payable is ranked lower than
55% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. BIO.B: 49.51 )
Ranked among companies with meaningful Days Payable only.
BIO.B' s Days Payable Range Over the Past 10 Years
Min: 43.27  Med: 52.39 Max: 56.81
Current: 49.51
43.27
56.81

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 7.32
BIO.B's Price/Net Current Asset Value is ranked lower than
52% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.00 vs. BIO.B: 7.32 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIO.B' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.86  Med: 6.53 Max: 95.94
Current: 7.32
2.86
95.94
Price/Tangible Book 2.31
BIO.B's Price/Tangible Book is ranked higher than
76% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.65 vs. BIO.B: 2.31 )
Ranked among companies with meaningful Price/Tangible Book only.
BIO.B' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.14  Med: 2.78 Max: 6.43
Current: 2.31
1.14
6.43
Price/Projected FCF 1.36
BIO.B's Price/Projected FCF is ranked higher than
74% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. BIO.B: 1.36 )
Ranked among companies with meaningful Price/Projected FCF only.
BIO.B' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.25 Max: 17.2
Current: 1.36
0.78
17.2
Price/Median PS Value 1.33
BIO.B's Price/Median PS Value is ranked lower than
77% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.95 vs. BIO.B: 1.33 )
Ranked among companies with meaningful Price/Median PS Value only.
BIO.B' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 0.90 Max: 1.36
Current: 1.33
0.24
1.36
Price/Graham Number 1.99
BIO.B's Price/Graham Number is ranked higher than
72% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. BIO.B: 1.99 )
Ranked among companies with meaningful Price/Graham Number only.
BIO.B' s Price/Graham Number Range Over the Past 10 Years
Min: 0.69  Med: 1.63 Max: 3.94
Current: 1.99
0.69
3.94
Earnings Yield (Greenblatt) (%) 4.20
BIO.B's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.90 vs. BIO.B: 4.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIO.B' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.8  Med: 7.70 Max: 11.9
Current: 4.2
3.8
11.9
Forward Rate of Return (Yacktman) (%) -6.52
BIO.B's Forward Rate of Return (Yacktman) (%) is ranked lower than
78% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.61 vs. BIO.B: -6.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIO.B' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.6  Med: 11.10 Max: 22.4
Current: -6.52
-6.6
22.4

More Statistics

Revenue (TTM) (Mil) $2,018
EPS (TTM) $ 3.66
Beta0.72
Short Percentage of Float0.05%
52-Week Range $124.50 - 151.22
Shares Outstanding (Mil)29.40
» More Articles for BIO.B

Headlines

Articles On GuruFocus.com
David Herro: Brexit Reaction Jun 24 2016 
How Will the Brexit Affect Small-Caps? - Royce Funds Commentary Jun 24 2016 
Steve Mandel Exits Position in Williams Companies in 1st Quarter Jun 24 2016 
This Sparkling Water Maker Rallies Forward Jun 24 2016 
Joel Greenblatt Invests in Swift Transportation Jun 24 2016 
British Pound Exchange Rates Plummet Post Brexit Jun 24 2016 
Why I Built a Liquid Alternative Robo Advisor Jun 24 2016 
DineEquity Positioned for Growth Jun 24 2016 
Under Armour's P/S Ratio Near Its 10-Year Low Jun 23 2016 
Conflicting Views Exist about the Tesla-SolarCity Acquisition Jun 23 2016 

More From Other Websites
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular... May 23 2016
Bio-Rad Laboratories, Inc. :BIO.B-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
Bio-Rad posts 1Q profit May 05 2016
Bio-Rad posts 1Q profit May 05 2016
Bio-Rad posts 1Q profit May 05 2016
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent May 05 2016
Bio-Rad to Report First-Quarter 2016 Financial Results Thursday, May 5, 2016 Apr 13 2016
Bio-Rad Laboratories, Inc. Earnings Analysis: 2015 By the Numbers Feb 29 2016
Bio-Rad Announces CE IVD Marking of Its QX200 Droplet Digital PCR System for Use as an In Vitro... Feb 25 2016
Bio-Rad Reports Fourth-Quarter and Full-Year 2015 Financial Results Feb 25 2016
CORRECTION - Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday,... Feb 16 2016
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer Feb 08 2016
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016 Feb 02 2016
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated Jan 12 2016
Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics Jan 11 2016
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters Jan 05 2016
Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : December 25,... Dec 25 2015
Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets Dec 21 2015
FDA Okays Bio-Rad D-100 for HbA1c (Diabetes) Testing Dec 21 2015
Bio-Rad Laboratories, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)